key: cord-0842746-xnicsz9t
authors: Rice, Adrian; Verma, Mohit; Shin, Annie; Zakin, Lise; Sieling, Peter; Tanaka, Shiho; Balint, Joseph; Dinkins, Kyle; Adisetiyo, Helty; Morimoto, Brett; Higashide, Wendy; Taft, Justin; Patel, Rosheel; Buta, Sofija; Martin-Fernandez, Marta; Bogunovic, Dusan; Spilman, Patricia; Gabitzsch, Elizabeth; Safrit, Jeffrey T.; Rabizadeh, Shahrooz; Niazi, Kayvan; Soon-Shiong, Patrick
title: The Dual-Antigen Ad5 COVID-19 Vaccine Delivered as an Intranasal Plus Subcutaneous Prime Elicits Th1 Dominant T-Cell and Humoral Responses in CD-1 Mice
date: 2021-03-26
journal: bioRxiv
DOI: 10.1101/2021.03.22.436476
sha: d7ddfd341ee85c767edd13d05a5f3865520b7ea1
doc_id: 842746
cord_uid: xnicsz9t

In response to the need for an efficacious, thermally-stable COVID-19 vaccine that can elicit both humoral and cell-mediated T-cell responses, we have developed a dual-antigen human adenovirus serotype 5 (hAd5) COVID-19 vaccine in formulations suitable for subcutaneous (SC), intranasal (IN), or oral delivery. The vaccine expresses both the SARS-CoV-2 spike (S) and nucleocapsid (N) proteins using an hAd5 platform with E1, E2b, and E3 sequences deleted (hAd5[E1-, E2b-, E3-]) that is effective even in the presence of hAd5 immunity. In the vaccine, S is modified (S-Fusion) for enhanced cell-surface display to elicit humoral responses and N is modified with an Enhanced T-cell Stimulation Domain (N-ETSD) to direct N to the endosomal/lysosomal pathway to increase MHC I and II presentation. Initial studies using subcutaneous (SC) prime and SC boost vaccination of CD-1 mice demonstrated that the hAd5 S-Fusion + N-ETSD vaccine elicits T-helper cell 1 (Th1) dominant T-cell and humoral responses to both S and N. We then compared SC to IN prime vaccination with either an SC or IN boost post-SC prime and an IN boost after IN prime. These studies reveal that IN prime/IN boost is as effective at generating Th1 dominant humoral responses to both S and N as the other combinations, but that the SC prime with either an IN or SC boost elicits greater T cell responses. In a third study to assess the power of the two routes of delivery when used together, we used a combined SC plus IN prime with or without a boost and found the combined prime alone to be as effective as the combined prime with either an SC or IN boost in generating both humoral and T-cell responses. The findings here in CD-1 mice demonstrate that combined SC and IN prime-only delivery has the potential to provide broad immunity – including mucosal immunity – against SARS-CoV-2 and supports further testing of this delivery approach in additional animal models and clinical trials.

In response to the need for a COVID-19 vaccine that is safe, effective, and suitable for global 51 distribution, we have developed the dual antigen hAd5 S-Fusion + N-ETSD vaccine including Specifically, removal of the E2b regions confers advantageous immune properties by minimizing 60 immune responses to Ad5 viral proteins such as viral fibers, 4 thereby eliciting potent immune 61 responses to specific antigens in patients with pre-existing adenovirus (Ad) immunity. 5, 6 Since 62 these deletions allow the hAd5 platform to be efficacious even in the presence of existing Ad 63 immunity, this platform enables relatively long-term antigen expression without significant 64 induction of anti-vector immunity. It is therefore also possible to use the same vector/construct for 65 homologous prime-boost therapeutic regimens. 7 Importantly, this next generation Ad vector has 66 demonstrated safety in over 125 patients with solid tumors. In these Phase I/II studies, CD4+ and 67 CD8+ antigen-specific T cells were successfully generated to multiple somatic antigens (CEA, 68 MUC1, brachyury) even in the presence of pre-existing Ad immunity. (E) -as well as the viral membrane and genomic RNA. The S glycoprotein 9-11 is displayed as a 72 trimer on the viral surface, whereas N is located within the viral particle ( Supplementary Fig. S1B) . have altered RBD sequences that may not be as effectively recognized by antibodies generated in 83 response to first-wave S-based vaccines. 84

To lessen the risk of single-antigen delivery and to broaden protective immune responses, we 85 included the N protein in our hAd5 S-Fusion + N-ETSD vaccine ( Supplementary Fig. S1C ). N is 86 a highly conserved and antigenic SARS-CoV-2-associated protein that has been studied previously 87 as an antigen in coronavirus vaccine design for SARS-CoV. 20-23 N associates with viral RNA and 88 has a role in viral RNA replication, virus particle assembly, and release. 24 The ability of N to elicit vigorous T-cell responses highlights another advantage of the addition 93 of N. A robust T-cell response to vaccination is at least as important as the production of antibodies 94 28 and should be a critical consideration for COVID-19 vaccine efficacy. First, humoral and T-cell 95 responses are highly correlated, with titers of neutralizing antibodies being proportional to T-cell 96 levels, suggesting the T response is necessary for an effective humoral response. 29 It is well 97 established that the activation of CD4+ T helper cells enhances B-cell production of antibodies. 98

Second, virus-specific CD4+ and CD8+ T cells are widely detected in COVID-19 patients, 30 based 99 on findings from patients recovered from the closely-related SARS-CoV, and there are reports that 100 such T cells persist for at least 6-17 years, suggesting that T cells may be an important part of 101 long-term immunity. [31] [32] [33] These T-cell responses were predominantly to N, as described in Le Bert 102 et al., who found that in all 36 convalescent COVID-19 patients in their study, the presence of 103 CD4+ and CD8+ T cells recognizing multiple regions of the N protein could be demonstrated. 33 104

They further examined blood from 23 individuals who had recovered from SARS-CoV and found 105 that the memory T cells acquired 17 years ago also recognized multiple proteins of SARS-CoV-2. 106

These findings emphasize the importance of designing a vaccine with the highly conserved 107 nucleocapsid present in both SARS-CoV and SARS-CoV-2. Third, recovered patients exposed to 108 SARS-CoV-2 have been found without seroconversion, but with evidence of T-cell responses. 34 109

The T-cell based responses become even more critical given the finding in at least one study that 110 neutralizing antibody titers decline in some COVID-19 patients after about 3 months. 35 The 111

importance of both S and N was highlighted by Grifoni et al. 15 who identified both S and N 112 antigens as a priori potential B and T-cell epitopes for the SARS-CoV virus that shows close 113 similarity to SARS-CoV-2 that are predicted to induce both T and B cell responses. 

In this initial study to test an SC hAd5 S-Fusion + N-ETSD prime followed by an SC boost, 162 CD-1 female mice received 1 x 10 10 viral particles (VP) of either hAd5 Null or the vaccine, both 163 n = 5, on Days 0 and 21. Mice were euthanized and tissue collected for analysis on Day 28 (Fig.  164   1A) . 165

Vaccinated mice generated anti-S antibodies that were shown to be neutralizing in surrogate 166 and live virus assays (Fig. 1B , C, and D, respectively). Vaccinated mice also generated anti-N 167 antibodies (Fig. 1E) , and both the anti-S and anti-N antibodies were Th1 dominant (Fig. 1F) . 168

Our neutralization data with live SARS-CoV-2 virus demonstrated the potency of the antibody 169 response generated following vaccination with hAd5 S-Fusion + N-ETSD, with evidence of high 170 neutralization even at a high dilution factor. In addition, a synergistic effect of pooled sera was 171 evident, with potent neutralization even greater than control convalescent serum at ≥ 1:1,000 172 dilution. Intracellular cytokine staining (ICS) revealed that the N peptide pool stimulated interferon-g 189 (IFN-g) and tumor necrosis factor alpha (TNF-a) production in selected CD4+ T-lymphocytes 190 from vaccinated but not hAd5 Null mice ( Fig. 2A and B) . Conversely, the S1 peptide pool 191 (containing S RBD) elicited higher IFN-g/TNF-a production in CD8+ T-lymphocytes than the N 192 peptide pool ( Fig. 2C and D) . ELISpot showed N peptides stimulated higher IFN-g secretion than 193 the S1 peptide pool, but cytokine secretion was greater with both stimuli in T-cells from vaccinated 194 mice as compared to Null (Fig. 2E ). IL-4 secretion was very low, therefore the T-cell responses, 195 like humoral responses, were Th1 dominant with the IFN-g/IL-4 ratio being >1 in 4 of 5 vaccinated 196 mice ( Fig. 2F and G) . Mice in all vaccinated groups produced anti-S IgG and overall, levels were the highest in sera 220 from IN > IN group mice (Fig. 3B ). Sera were highly neutralizing as reflected by high inhibition 221 in the surrogate virus neutralization assay (Fig. 3C) . Anti-N IgG was also detected in sera from all 222 vaccinated mice, with the levels being very similar between vaccinated groups (Fig. 3D) . group mice showed high inhibition in the surrogate neutralization assay, whereas homogenate from 226 4 mice in the SC > SC boost group did not surpass the 35% level of inhibition that is associated 227 with viral neutralization (Fig. 3F) . In lung homogenate, anti-N IgG showed a trend to higher in the 228 SC > IN group (Fig. 3G ). Not unexpectedly, both anti-S and anti-N IgA levels in lung homogenate 229 were highest in the IN > IN boost group (Fig. 3H) . Furthermore, the anti-S and anti-N responses 230 in both sera and lung were highly Th1 dominant for all vaccinated groups (Fig. 3I) . antibodies where values greater than 1 represent Th1 dominance. Statistical analyses performed 241

using One-way ANOVA with Tukey's post-hoc analysis comparing each group to every other 242 group where *p < 0.05; **p ≤ 0.01; ***p ≤ 0.001; and ****p ≤ 0.0001. 243 244

Intracellular cytokine staining (ICS) of IFN-g (Fig. 4A, D) ; IFN-g, TNF-a (Fig. 4B, E) , and 246 IFN-g, TNF-a, interleukin-2 (IL-2) (Fig. 4C, F) showed the highest mean values for the SC > SC 247 boost and SC > IN vaccinated groups with responses to the N peptide pool trending higher for both 248 CD4+ and CD8+ T cells. This was somewhat in contrast with the findings of the first SC > SC 249 boost study (study 1 above) where CD8+ T-cell responses were greater to the S1 peptide pool (Fig.  250 2C), however, variation is expected in outbred CD-1 mice and robust CD8+ responses to both S 251 and N were detected in SC > SC mice from each study. While the differences were not statistically 252 to the N peptide pool (Fig. 4G ). Interleukin-4 (IL-4) secretion in ELISpot was very low for all 258 groups (Fig. 4H) , therefore the IFN-g/IL-4 ratios were above 1 for almost all vaccinated mice in 259 response to both S and N peptide pools (Fig. 4I) . 260

The T-cell responses in this study suggested an important contribution of SC delivery to T cell 261 responses. post-hoc analysis comparing treatment groups within each antibody subtype or groups in the 306 neutralization assay where *p < 0.05 and ** p ≤ 0.01. 307 308

Similar to the findings in the first study, ICS shows the N peptide pool stimulated cytokine 311 production by CD4+ T lymphocytes from all vaccinated mice (Fig. 6A-C) , but CD8+ T cells from 312 vaccinated mice responded to S peptide pool 1 which contains the S RBD (Fig. 6D-F) . The 313 differences between vaccinated groups were not significant due to variability amongst mice, with 314 SC/IN > no boost vaccinated mice having T-cell responses that were similar to those seen with 315 mice that did receive boosts. 316

In ELISpot, the highest IFN-g secretion in response to peptide pools differed by both peptide 317 pool and vaccination regimen. As compared to the negative control (SIV nef), T cell IFN-g 318 secretion was significantly greater for the combined SC/IN > SC group in response to the S1 319 peptide pool; greater for the SC/IN > IN group to the S2 peptide pool; and greater for the SC/IN > 320 no boost group to the N peptide pool (Fig. 6G) . 321 IL-4 secretion was again very low (Fig. 6H) , therefore the IFN-g/IL-4 ratio was above 1 for 322 all vaccinated mice with only one exception, reflecting Th1 dominance of T-cell responses (Fig.  323   6I) . The key finding here that prime-only vaccination delivered by combination SC and IN dosing 371 results in broad humoral and T-cell responses, with the potential for enhanced mucosal immunity, 372 supports the ongoing clinical testing of the hAd5 S-Fusion + N-ETSD. The vaccine has currently 373 completed Phase 1 testing as an SC prime and SC boost, and oral boost formulations that have 374

shown efficacy in the ability to elicit both humoral and T-cell responses that conferred complete 375 protection against high-titer SARS-CoV-2 challenge in our pre-clinical studies in non-human 376

primates, 1 will soon also be tested in the clinic. To our knowledge, our vaccine is currently the 377 only one available in SC, thermally-stable oral, 51 For studies here, the next generation hAd5 [E1-, E2b-, E3-] vector was used (Fig. S1A) translated N to the endosomal/lysosomal pathway. 2 The SARS-CoV-2 S protein is found on the 580 viral surface 11 and the N protein is found in the interior of the virus 23,56 (Fig. S1B ). 581

The powerful cytomegalovirus (CMV) promoter 57 drives expression in the hAd5 construct 582 (Fig. S1C) . To determine surface expression of the RBD epitope by vaccine candidate constructs, we 597

transfected HEK 293T cells with hAd5 construct DNA and quantified surface RBD by flow 598 cytometric detection using anti-RBD antibodies. The constructs tested were: S-WT, S-WT + N-599

Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 385 Challenge by Antibody Plus Th1 Dominant N-and S-Specific T-Cell Responses to 386 Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an 387 NHP Study. bioRxiv

Th1 Dominant Nucleocapsid and Spike Antigen-Specific CD4+ and CD8+

Memory T Cell Recall Induced by hAd5 S-Fusion + N-ETSD Infection of Autologous 390 Dendritic Cells from Patients Previously Infected with SARS-CoV-2. medRxiv

Improved adenovirus packaging cell lines 393 to support the growth of replication-defective gene-delivery vectors

Production and Characterization of Improved Adenovirus Vectors 397 with the E1, E2b, and E3 Genes Deleted

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 400 (CEA/MUC1/Brachyury)-Based Immunotherapy Vaccine Regimen in Patients with 401 Advanced Cancer

Coronaviruses: an overview of their replication and 489 pathogenesis

Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential 492 Implications for Reducing Transmission of COVID-19

IgA dominates the early neutralizing antibody response to SARS-CoV-2

A SARS-CoV-2 surrogate virus neutralization test based on antibody-497 mediated blockage of ACE2-spike protein-protein interaction

Multifunctional TH1 cells define a correlate of vaccine-mediated 500 protection against Leishmania major

SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster 503 is common to both exogenous recombinant and endogenous DNA-encoded 504 immunogens

Immune responses to T-cell epitopes of SARS CoV-N protein are enhanced 506 by N immunization with a chimera of lysosome-associated membrane protein

HIV-1-specific cytotoxicity is preferentially mediated by a subset of 509 CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha

HIV nonprogressors preferentially maintain highly functional HIV-512 specific CD8+ T cells

Shaping successful and unsuccessful CD8 T cell responses 514 following infection

T cell 517 responses to viral infections -opportunities for Peptide vaccination

T-cell quality in memory and protection: 520 implications for vaccine design

Use of adenovirus as a model system to illustrate a 523 simple method using standard equipment and inexpensive excipients to remove live 524 virus dependence on the cold-chain

Safety, tolerability, and immunogenicity of a recombinant adenovirus 527 type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-528 in-human trial

Gibco Cat# 11995-065) with 10% FBS and 1X PSA (100 601 units/mL penicillin, 100 µg/mL streptomycin, 0.25 ug/mL Amphotericin B) at 37 o C. Cells were 602 transfected with 0.5 µg of hAd5 plasmid DNA using a JetPrime transfection reagent (Polyplus 603 Catalog # 89129-924) according to the manufacturer's instructions. Cells were harvested 1, 2, 3, 604 and 7 days post transfection by gently pipetting cells into medium and labeled with an anti-RBD 605 monoclonal antibody (clone D003 Sino Biological Catalog # 40150-D003) and F(ab')2-Goat anti-606 Human IgG-Fc secondary antibody conjugated with R-phycoerythrin (ThermoFisher Catalog # 607 H10104)

for 2 days and harvested for 614 ACE2-Fc binding analysis. Recombinant ACE2-IgG1Fc protein was produced using Maxcyte 615 transfection in CHO-S cells that were cultured for 14 days. ACE2-IgG1Fc was then purified using 616 a MabSelect SuRe affinity column on AKTA Explorer. Purified ACE2-IgG1Fc was dialyzed into 617 10 mM HEPES, pH7.4, 150 mM NaCl and concentrated to 2.6 mg/mL. For binding studies, the 618 ACE2-IgG1Fc was used at a concentration of 1 µg/mL for binding. Cells were incubated with 619 ACE2-Fc for 20 minutes and, after a washing step, were then labeled with a PE conjugated F(ab')2-620 goat anti-human IgG Fc secondary antibody at a 1:100 dilution, incubated for 20 minutes

Mice 628 were administered subcutaneous (SC) injections at the indicated doses in 50 µL ARM buffer (20 629 mM Tris pH 8.0, 25 mM NaCl, with 2.5% glycerol) or intranasal (IN) injections at the indicated 630 doses in 10 µL ARM buffer (5 µL per nostril) while under isoflurane anesthesia. On the final day 631 of each study, blood was collected via the submandibular vein from isoflurane-anesthetized mice 632 for isolation of sera using a microtainer tube and then mice were euthanized for collection of spleen 633 and lungs. 634 Spleens were removed from each mouse and placed in 5 mL of sterile media 635 (RPMI/HEPES/Pen/Strep/10% FBS)

Lungs were removed from each mouse, dissected in half and then immediately snap frozen 638 on dry ice. Lung homogenates were generated by thawing one frozen lung half and homogenizing 639 in 150 µL sterile PBS using a Fisher Scientific pestle drill. Homogenates were centrifuged at 640 13,000 rpm for 3 minutes and supernatants were utilized in ELISA and cPass surrogate 641 neutralization assays

Intracellular cytokine stimulation (ICS)

ICS assays were performed using 10 6 live splenocytes per well in 96-well U-bottom plates

GolgiStop (BD) added two hours after initiation of incubation. The S 649 peptide pool (JPT: Cat #PM-WCPV-S-1) is a total of 315 spike peptides split into two pools 650 comprised of 158 and 157 peptides each. The N peptide pool (JPT; Cat # PM-WCPV-NCAP-1) 651 was also used to stimulate cells. A SIV-Nef peptide pool (BEI Resources) was used as an off-target 652 negative control. Stimulated splenocytes were then stained for a fixable cell viability stain 653 followed by the lymphocyte surface markers CD8b and CD4, fixed with CytoFix (BD), 654 permeabilized, and stained for intracellular accumulation of IFN-γ, TNF-α and IL-2 (in studies 2

IFN-γ (clone XMG1.2, BD), TNF-α (clone MP6-XT22, 657 BD) and IL-2 (clone

and staining was performed in the presence of unlabeled 658 anti-CD16/CD32 antibody (clone 2.4G2; BD)

Coulter Cytoflex S flow cytometer and analyzed using Flowjo Software

ELISpot assays were used to detect cytokines secreted by splenocytes from inoculated mice

The cells (2-4 x 10 5 cells per well of a 96-well plate) were added to the ELISpot 666 plate containing an immobilized primary antibodies to either IFN-g or IL-4 (BD), and were 667 exposed to various stimuli (e.g. control peptides, target peptide pools/proteins) comprising 2 668 µg/mL peptide pools or 10 µg/mL protein for 36-40 hours. After aspiration and washing to remove 669 cells and media, extracellular cytokine was detected by a secondary antibody to cytokine 670 conjugated to biotin (BD). A streptavidin/horseradish peroxidase conjugate was used detect the 671 biotin-conjugated secondary antibody. The number of spots per well

For IgG antibody detection in sera and lung homogenate from inoculated mice, ELISAs 679 specific for spike and nucleocapsid antibodies, as well as for IgG subtype (IgG1, IgG2a, IgG2b, 680 and IgG3) antibodies were used. In addition, for IgA antibody detection in lung homogenate from 681 inoculated mice, ELISAs specific for spike and nucleocapsid antibodies, as well as for IgA was 682 used

full-length S with fibritin trimerization domain, constructed and purified in-house 684 by ImmunityBio), SARS-CoV-2 S RBD (Sino Biological

The 687 wells were washed three times with 250 µL PBS containing 1% Tween 20 (PBST) to remove 688 unbound protein and the plate was blocked for 60 minutes at room temperature with 250 µL PBST

After blocking, the wells were washed with PBST, 100 µL of either diluted serum or diluted lung 690 homogenate samples were added to wells, and samples incubated for 60 minutes at room 691 temperature. After incubation, the wells were washed with PBST and 100 µL of a 1/5000 dilution 692 of anti-mouse IgG HRP (GE Health Care

or anti-mouse IgG2a HRP (Sigma; Cat # SAB3701178), or anti-mouse IgG2b HRP 694 (Sigma; catalog# SAB3701185), anti-mouse IgG3 HRP conjugated antibody (Sigma; Cat # 695 SAB3701192), or anti-mouse IgA HRP conjugated antibody (Sigma; Cat # A4789) was added to 696 wells. For positive controls, a 100 µL of a 1/5000 dilution of rabbit anti-N IgG Ab or 100 µL of a 697 1/25 dilution of mouse anti-S serum (from mice immunized with purified S antigen in adjuvant) 698 were added to appropriate wells. After incubation at room temperature for 1 hour, the wells were 699 washed with PBS-T and incubated with 200 µL o-phenylenediamine-dihydrochloride (OPD 700 substrate (Thermo Scientific Cat # A34006) until appropriate color development. The color 701 reaction was stopped with addition of 50 µL 10% phosphoric acid solution (Fisher Cat # A260-702 500)

Using these values, we were able to calculate 709 that hAd5 S-Fusion + N-ETSD vaccination generated a geometric mean value for S-and N-710 specific IgG per milliliter of serum. These values were also used to generate a Th1/Th2 ratio for 711 the humoral responses by dividing the sum total of Th1 skewed antigen-specific IgG isotypes 712 (IgG2a, IgG2b and IgG3) with the total Th2 skewed IgG3, for each mouse. Some responses, 713 particularly for anti-N responses in IgG2a and IgG2b (both Th1 skewed isotypes), were above the 714 limit of quantification with OD values higher than those observed in the standard curve

721 antibody-detection-Kit.html) for detection of neutralizing antibodies was used according to the 722 manufacturer's instructions. 58 The kit detects circulating neutralizing antibodies against

Vero e6 kidney epithelial cells from Cercopithecus aethiops (ATCC CRL-1586) 732 were plated at 20,000 cells/well in a 96-well format and 24 hours later, cells were incubated with 733 antibodies or heat inactivated sera previously serially diluted in 3-fold steps in DMEM containing 734 2% FBS, 1% NEAAs, and 1% Pen-Strep; the diluted samples were mixed 1:1 with SARS-CoV-2 735 in DMEM containing 2% FBS, 1% NEAAs, and 1% Pen-Strep at 10,000 TCID50/mL for 1 hr. at 736 37 o C, 5% CO2. This incubation did not include cells to allow for neutralizing activity to occur 737 prior to infection. The samples for testing included sera from the four mice that showed anti-S 738 IgG2a and IgG2b antibody responses in Fig. 1B, pooled sera from those four mice, sera from a COVID-19 convalescent patient, and media only. For detection of neutralization

Control wells including 6 wells on each plate for no virus and virus-only controls were used. The 743 percent neutralization was calculated as 100-((sample of interest

Enhanced HEK 293T cell-surface expression of RBD following transfection with Ad5 S-750 Fusion + N-ETSD 751 752 As shown in Figure S2, anti-RBD-specific antibodies did not detect RBD on the surface of 753 HEK 293T cells transfected with hAd5 S-WT (Fig. 2A) or hAd5 S-WT + N-ETSD (Fig. 2B) 754 constructs, while hAd5 S-Fusion alone was higher (Fig. 2C). Notably, the highest cell-surface 755 expression of RBD was detected after transfection with dual antigen hAd5 S-Fusion + N-ETSD 756 (Fig. 2D). Similar results were seen for recombinant ACE2-Fc binding to S-WT, S-Fusion and S-757

These findings support our 759 proposition that an hAd5 S-Fusion + N-ETSD construct, containing a high number and variety of 760 antigens provided by both full-length, optimized S with proper folding and N leads to enhanced 761 expression and cell surface display of

Flow cytometric analysis of an anti-RBD 766 antibody with construct-transfected cells reveals no detectable surface expression of RBD in either 767 (A) S-WT or (B) S-WT + N-ETSD transfected cells. Expression was higher in (C) S-Fusion 768 transfected cells as compared to S-WT

Fusion + N-ETSD transfected cells, particularly at day 1 and 2. (E) No expression was detected 770 the N-ETSD negative control. Recombinant ACE2-Fc binding to (F) S-WT, (G) and S-Fusion, and 771 (H) S-Fusion + N-ETSD is shown

We thank Phil Yang of ImmunityBio for his ongoing coordination of project reports for this study. 382 383